Ken Griffin Puma Biotechnology, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$2.25 - $4.03 $33,300 - $59,644	-14,800 Reduced 80.0%	3,700 $9,000
Q1 2024 May 15, 2024	BUY	$4.29 - $7.4 $56,628 - $97,680	13,200 Added 249.06%	18,500 $98,000
Q4 2023 Feb 14, 2024	SELL	$2.23 - $4.49 $33,004 - $66,452	-14,800 Reduced 73.63%	5,300 $22,000
Q3 2023 Nov 14, 2023	BUY	$2.63 - $4.09 $23,933 - $37,219	9,100 Added 82.73%	20,100 $52,000
Q2 2023 Aug 14, 2023	BUY	$2.6 - $3.58 $5,200 - $7,160	2,000 Added 22.22%	11,000 $38,000
Q1 2023 May 15, 2023	SELL	$2.21 - $4.82 $12,155 - $26,510	-5,500 Reduced 37.93%	9,000 $27,000
Q4 2022 Feb 14, 2023	SELL	$2.12 - $5.08 $8,904 - $21,336	-4,200 Reduced 22.46%	14,500 $61,000
Q3 2022 Nov 14, 2022	BUY	$2.27 - $3.84 $42,449 - $71,808	18,700 New	18,700 $44,000

101

29M

50.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $137M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.